cbas-hero-nav-img-l-v5

CBAS Heparin Surface

Proven heparin bonding technology for lasting thromboresistance

References

  1. Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J. Heparin surfaces: impact of immobilization chemistry on hemocompatibility and protein adsorption. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2014;102(8):1817-1824.
  2. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437.
  3. Freeman J, Chen A, Weinberg RJ, Okada T, Chen C, Lin PH. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded PTFE Propaten Graft in a chronic canine femoral artery bypass model. Annals of Vascular Surgery 2018;49:295-303. 
  4. Biran R, Pond D. Heparin coatings for improving blood compatibility of medical devices. Advanced Drug Delivery Reviews 2017;112:12-23. 
  5. Carmeda AB. Carmeda® BioActive Surface (also known as CBAS® Heparin Surface) Reference List. Upplands Väsby, Sweden: Carmeda AB; 2019. [Reference list]

Featured Gore Products with CBAS Heparin Surface

propaten-CBAS-cardimg

GORE® PROPATEN® Vascular Graft

50% reduction in the risk of graft occlusion compared to standard ePTFE in Critical Limb Ischemia (CLI) patients 1
 

Learn more >


1. Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian Propaten® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomised clinical controlled multi-centre trial. European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.

 

 

 

 

 

propaten-CBAS-cardimg-3

GORE® VIABAHN® Endoprosthesis

An Investigational Device Exemption (IDE) Clinical Study of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface** in Japan demonstrated:

  • 88% 12-month primary patency in long, complex SFA lesions (n = 103)1
  • 21.8 cm average lesion length
  • 65.7% chronic total occlusions (CTOs)
  • 84.5% TASC II C&D lesions

 

Learn more >


** Heparin Bioactive Surface is synonymous with the CBAS Heparin Surface.

1. GORE® VIABAHN® Endoprosthesis Japan IDE Clinical Study demonstrated 12-month primary patency of 92% as defined by evidence of flow with no Target Lesion Revascularization (TLR). The same study demonstrated 88% 12-month primary patency when defined by PSVR of < 2.5 without a TLR.

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.